NKTR Trading Analysis - 11/06/2026 02:38 PM — TRU-SENTIMENT

NKTR (Nektar Therapeutics) at $37.15. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $23,710 vs put $0. RSI 52.4.

TRU-SENTIMENT · DeltaNeutral

NKTR Trading Analysis - 11/06/2026 02:38 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

NKTR (Nektar Therapeutics) at $37.15. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $23,710 vs put $0. RSI 52.4.

Symbol
NKTR
Price
$37.15
Article bias (separate from True Sentiment)
bullish
Conviction
low
Published
2026-11-06 14:38:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From the embedded TRUE SENTIMENT OPTIONS data:

Call Dollar Volume: $23,710.00 (100.00%) Put Dollar Volume: $0.00 (0.00%) Total: $23,710.00

  • Sentiment is Bullish with 24 call contracts vs 0 put contracts, 3 call trades vs 0 put trades.
  • Only 3 of 516 total options analyzed met the Delta 40-60 filter (0.60% filter ratio) — small pure directional sample.
  • Read suggests near-term upside conviction from directional call buyers despite bearish technicals.
  • Divergence: Option spread engine flagged "Options sentiment is Bullish but technicals are Bearish" and advised waiting for alignment.
Note: Options flow shows 100% call dollar volume in Delta 40-60 bucket, but total sample is only 3 contracts.

Key Statistics: NKTR

$37.15 +2.61%
52-Week Range
$33.40 - $109.00
Market Cap
$1.27B
P/E (TTM)
4.50
PEG Ratio
N/A
Beta
1.34
Next Earnings
N/A
Avg Volume
$731,170
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)4.50
EPS (trailing 12 mo)$-2.87
Market cap$1.27B
Shares outstanding34.1M

Dividend

Dividend yield0.00%

Risk & range

Beta1.34
52-week low$33.40
52-week high$109.00
Historical volatility90.8%

Ownership & trading

Institutional ownership45.4%
Average daily volume0.8M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following items are based on general knowledge of Nektar Therapeutics (NKTR) and are provided as context only, separate from the data-driven analysis below.

  • NKTR previously announced strategic pipeline reprioritization focused on its immunology programs, reducing burn but raising questions on late-stage catalysts.
  • Recent biotech sector weakness and a broad risk-off move in small-cap pharmaceuticals pressured speculative names including NKTR.
  • No confirmed near-term FDA catalyst has been scheduled per public knowledge; any trial readout would be a volatile binary event.
  • Context: The embedded data shows a steep multi-week decline from the $60s to high-$30s, consistent with a loss of momentum despite isolated bullish options flow.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

  • Trailing P/E is listed at 4.50, but Trailing EPS is -2.87, indicating the company is not profitable; the positive P/E is non-meaningful due to negative earnings.
  • Forward P/E, PEG Ratio, Profit Margins, ROE, Revenue Growth, Total Revenue, and Free Cash Flow are all null — no margin or growth trend can be calculated.
  • Market Cap is $1,268,241,735.00 with Shares Outstanding of 34,143,000.00 and Institutional Ownership at 45.41%.
  • 52-Week High is $109.00 and 52-Week Low is $33.40; current embedded price (~$36.20) sits near the low end of the annual range.
  • Beta is 1.34 and Historical Volatility is 90.78%, reflecting elevated systematic and idiosyncratic risk.
  • Analyst consensus, target mean price, and recommendation key are null — no street consensus available in data.
  • Fundamentals show a loss-making micro-cap biotech with high volatility and no provided revenue/margin profile, diverging from the bullish options sentiment flagged in the embedded flow.

Current Market Position

From the embedded minute and daily data:

  • Daily close on 2026-11-05 was $36.20, down from $38.15 on 2026-11-04 and an intraday low of $35.76.
  • Minute bars from 2026-11-05 09:30 to 2026-11-06 14:10 show opening at $38.36, drifting to $37.15 by final bar, with thin late-session volume (7744 then 842).
  • Recent daily range low was $35.61 (2026-10-16); current price is just above that structural low.
Support
$35.61
Resistance
$38.15
Last Close
$36.20
Upper Band
$40.37
Lower Band
$35.48

Technical Analysis

Technical Indicators

RSI (14)
52.39
MACD
-3.93
MACD Signal
-3.14
MACD Hist
-0.79
SMA 5
37.54
SMA 20
37.92
SMA 50
52.70
BB Lower
35.48
BB Middle
37.92
BB Upper
40.37
ATR 14
1.64
  • Price ($36.20) is below SMA 5 ($37.54), SMA 20 ($37.92), and far below SMA 50 ($52.70) — bearish alignment with no golden cross.
  • RSI at 52.39 is neutral, not confirming strong downside or upside momentum.
  • MACD (-3.93) below signal (-3.14) with negative histogram (-0.79) shows bearish momentum persisting.
  • Bollinger Bands: price is between lower ($35.48) and middle ($37.92); no squeeze flagged, bands are wide given HV.
  • 30-day range high $62.40, low $35.61; price is near the bottom 5% of the 30-day range.

True Sentiment Analysis (Delta 40-60 Options)

From the embedded TRUE SENTIMENT OPTIONS data:

Call Dollar Volume: $23,710.00 (100.00%) Put Dollar Volume: $0.00 (0.00%) Total: $23,710.00

  • Sentiment is Bullish with 24 call contracts vs 0 put contracts, 3 call trades vs 0 put trades.
  • Only 3 of 516 total options analyzed met the Delta 40-60 filter (0.60% filter ratio) — small pure directional sample.
  • Read suggests near-term upside conviction from directional call buyers despite bearish technicals.
  • Divergence: Option spread engine flagged "Options sentiment is Bullish but technicals are Bearish" and advised waiting for alignment.
Note: Options flow shows 100% call dollar volume in Delta 40-60 bucket, but total sample is only 3 contracts.

Key Price Levels (Observational Only)

Daily Low 30d
$35.61
BB Lower
$35.48
SMA 5
$37.54
SMA 20 / BB Mid
$37.92
BB Upper
$40.37

Interactive charts load with JavaScript. This text is the crawlable summary.